SCHEMBL15575367

SCHEMBL15575367

CNC(=O)c1cc(Oc2ccc(CNC(=O)Nc3cc(C)c(Cl)cc3OCCCCN(C)C)cc2)ccn1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DDR2 Q16832 5/20 0.60
GSK3B P49841 2/20 0.52
RAF1 P04049 11/20 0.48
KDR P35968 6/20 0.46
MAPK14 Q16539 4/20 0.43
BRAF P15056 3/20 0.43
EPHX2 P34913 3/20 0.43
RIPK2 O43353 2/20 0.43
ABCB11 O95342 2/20 0.43
ABL1 P00519 2/20 0.43
RET P07949 2/20 0.43
HTR1A P08908 2/20 0.43
PDGFRB P09619 2/20 0.43
ADORA3 P0DMS8 2/20 0.43
KIT P10721 2/20 0.43
FGFR1 P11362 2/20 0.43
PDGFRA P16234 2/20 0.43
FLT1 P17948 2/20 0.43
MAOA P21397 2/20 0.43
EPHA1 P21709 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL171214 0.98 DDR2 (0.60) DDR2GSK3BRAF1KDRMAPK14
SCHEMBL171021 0.95 DDR2 (0.65) DDR2GSK3BRAF1KDRMAPK14
SCHEMBL15573236 0.93 DDR2 (0.70) DDR2GSK3BRAF1KDRMAPK14
SCHEMBL16990690 0.92 DDR2 (0.61) DDR2GSK3BRAF1KDR
SCHEMBL15575220 0.92 DDR2 (0.61) DDR2GSK3BRAF1KDRMAPK14
SCHEMBL16990715 0.90 DDR2 (0.57) DDR2GSK3BRAF1KDRMAPK14
SCHEMBL15575411 0.90 DDR2 (0.71) DDR2GSK3BRAF1KDRMAPK14
SCHEMBL16990667 0.90 DDR2 (0.62) DDR2GSK3BRAF1KDR
SCHEMBL171157 0.89 DDR2 (0.56) DDR2GSK3BRAF1KDRMAPK14
SCHEMBL13603580 0.89 DDR2 (0.59) DDR2GSK3BRAF1KDRMAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150225369-A1 DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS MERCK PATENT GMBH (DE) 2015-08-13 US claimed
EP-2890380-A2 DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS Merck Patent GmbH (DE) 2015-07-08 EP claimed
WO-2014032755-A2 DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS MERCK PATENT GMBH (DE) 2014-03-06 WO claimed
US-20150225369-A1 DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS MERCK PATENT GMBH (DE) 2015-08-13 US disclosed
EP-2890380-A2 DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS Merck Patent GmbH (DE) 2015-07-08 EP disclosed
WO-2014032755-A2 DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS MERCK PATENT GMBH (DE) 2014-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150225369-A1 DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS DDR2, DDR1, DDRGK1 DDR2 1/4885GSK3B 494/4885RAF1 3072/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.